Corazon (corsee) D. Sanders - 20 Jun 2025 Form 4 Insider Report for Ultragenyx Pharmaceutical Inc. (RARE)

Role
Director
Signature
/s/ Karah Parschauer, attorney-in-fact
Issuer symbol
RARE
Transactions as of
20 Jun 2025
Net transactions value
-$89,923
Form type
4
Filing time
23 Jun 2025, 13:50:13 UTC
Previous filing
22 May 2025
Next filing
09 Sep 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Sanders Corazon (Corsee) D. Director C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO /s/ Karah Parschauer, attorney-in-fact 23 Jun 2025 0001796536

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RARE Common Stock Sale $89,923 -2,405 -14% $37.39 15,344 20 Jun 2025 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).